New CAR T-Cell Therapy Approved and Available at Roswell Park for Lymphoma Patients
October 14, 2020
October 14, 2020
BUFFALO, New York, Oct. 14 -- The Roswell Park Comprehensive Cancer Center issued the following news release:
Giving patients with relapsed or refractory mantle cell lymphoma (MCL) access to more treatment options, Roswell Park Comprehensive Cancer Center has been approved to administer the FDA-approved chimeric antigen receptor (CAR) T-cell therapy Tecartus. The immunotherapy drug is manufactured by Kite, a subsidiary of Gilead Sciences.
Tecartus, also known as brexuca . . .
Giving patients with relapsed or refractory mantle cell lymphoma (MCL) access to more treatment options, Roswell Park Comprehensive Cancer Center has been approved to administer the FDA-approved chimeric antigen receptor (CAR) T-cell therapy Tecartus. The immunotherapy drug is manufactured by Kite, a subsidiary of Gilead Sciences.
Tecartus, also known as brexuca . . .